SGLT2 Inhibitors in Type 1 Diabetes Mellitus: The Kidney and Heart Perspective.
文献摘要
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have become a cornerstone of cardio-kidney protection in type 2 diabetes, yet their role in type 1 diabetes remains incompletely defined. While randomized controlled trials in type 1 diabetes have consistently demonstrated improvements in glycemic control, body weight, and insulin requirements, they were not designed to assess cardiovascular or kidney outcomes. Consequently, current evidence for cardio-kidney protection in type 1 diabetes is derived largely from physiological studies, surrogate biomarkers, and observational data.Accumulating evidence however suggests potential kidney benefits in type 1 diabetes. Across clinical and real-world studies, SGLT2i has been associated with up to 40% reduction in albuminuria and attenuation of the estimated glomerular filtration rate (eGFR) decline. These observations are consistent with mechanistic studies demonstrating restoration of the tubuloglomerular feedback and reduction of the intraglomerular pressure as the principal kidney-protective mechanisms of SGLT2i. However, evidence for cardiovascular protection remains substantially more limited. Studies demonstrate improvements in several established cardiovascular risk factors, including reductions in body weight (up to 3.4 kg), systolic blood pressure (approximately 2-4 mmHg), and fasting glucose. Yet direct evidence for reductions of cardiovascular events, kidney failure, or mortality is currently unavailable.Despite these limitations, the potential for early kidney protection in type 1 diabetes is particularly attractive, given the long natural history of diabetic kidney disease and the opportunity for intervention before irreversible kidney damage occurs. However, the increased risk of diabetic ketoacidosis (DKA) remains the major obstacle to widespread use and regulatory approval of SGLT2i in this population. Careful patient selection, structured education, ketone body monitoring, and implementation of DKA risk-mitigation strategies are therefore essential when considering this therapy. Future studies incorporating dedicated cardio-kidney endpoints and advances such as continuous ketone body monitoring may help clarify the benefit-risk balance and determine whether SGLT2i can ultimately assume a broader role as adjunctive cardio-kidney protective therapy in type 1 diabetes.